Bryn Mawr Capital Management’s AstraZeneca AZN Stock Holding History

Bryn Mawr Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.27M	Buy	27,799 +41	+0.1%	+$7.71K	0.23%	104
2026 Q1	$5.47M	Buy	27,758 +57	+0.2%	+$11K	0.27%	90
2025 Q4	$5.09M	Buy	27,701 +92	+0.3%	+$16.1K	0.25%	92
2025 Q3	$4.24M	Sell	27,609 -5	-0%	-$757	0.21%	100
2025 Q2	$3.86M	Sell	27,614 -608	-2%	-$85.2K	0.21%	100
2025 Q1	$4.15M	Sell	28,222 -565	-2%	-$81.7K	0.25%	94
2024 Q4	$3.77M	Sell	28,787 -50	-0.2%	-$7K	0.2%	107
2024 Q3	$4.49M	Sell	28,837 -555	-2%	-$89.6K	0.24%	90
2024 Q2	$4.58M	Sell	29,392 -1,254	-4%	-$189K	0.25%	91
2024 Q1	$4.15M	Sell	30,646 -287	-0.9%	-$38K	0.24%	96
2023 Q4	$4.17M	Buy	30,933 +82	+0.3%	+$10.7K	0.26%	90
2023 Q3	$4.18M	Sell	30,851 -363	-1%	-$49.6K	0.27%	81
2023 Q2	$4.47M	Sell	31,214 -183	-0.6%	-$26.9K	0.42%	59
2023 Q1	$4.36M	Sell	31,397 -1,550	-5%	-$209K	0.45%	61
2022 Q4	$4.47M	Buy	+32,947	New	+$4.13M	0.48%	59

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bryn Mawr Capital Management's AZN Position: Q2 2026 in Review

Bryn Mawr Capital Management increased its AstraZeneca (AZN) stake by 0.15% in Q2 2026, buying an estimated $7.71K and bringing the position to 27,799 shares worth $5.27M. The position accounts for 0.23% of the portfolio, ranked #104.

Bryn Mawr Capital Management first reported a position in AZN in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.47M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Bryn Mawr Capital Management held 27,799 shares of AstraZeneca worth $5.27M as of Q2 2026.
Bryn Mawr Capital Management bought 41 AstraZeneca shares in Q2 2026, an estimated $7.71K.
AstraZeneca made up 0.23% of Bryn Mawr Capital Management's portfolio in Q2 2026, its #104 holding.
Bryn Mawr Capital Management first reported a position in AstraZeneca in Q4 2022 and has held it in 15 quarters since.
Bryn Mawr Capital Management's AstraZeneca position peaked at $5.47M in Q1 2026.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Bryn Mawr Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.